Spotlight on Dr. Toral Patel: Leading Brain Tumor Surgeon and Principal Investigator in the ReSPECT-GBM Clinical Trial

As part of our ongoing commitment to highlight the incredible medical professionals behind the ReSPECT-GBM clinical trial, today we are proud to feature Toral Patel, M.D., a renowned expert in brain tumor surgery and a Principal Investigator in our Phase 2 trial for recurrent glioblastoma (GBM).

Dr. Patel serves as the Director of the Brain Tumor Program at UT Southwestern Medical Center, where she is recognized for her innovative work in neurosurgical oncology. Her research has earned numerous accolades, and she has consistently been named to D Magazine’s “Best Doctors” list from 2018 to the present.

In addition to her clinical and research achievements, Dr. Patel is an active member of leading professional societies, including:

• Society for Neuro-Oncology (SNO)
• Congress of Neurological Surgeons (CNS)
• American Association of Neurological Surgeons (AANS)

Her dedication and leadership play a critical role in advancing the mission of Plus Therapeutics to improve treatment outcomes for patients facing glioblastoma, one of the most aggressive and treatment-resistant brain cancers.

Learn more about Dr. Patel and the ReSPECT-GBM trial: Read More

Now Enrolling: ReSPECT-GBM Clinical Trial

The ReSPECT-GBM trial is currently recruiting patients with recurrent glioblastoma to evaluate the safety and effectiveness of Rhenium-186 Obisbemeda, a novel targeted radiotherapeutic designed to deliver high-dose radiation directly into the tumor.

Interested in participating? Email our team at: respect@plustherapeutics.com

#RESPECTGBM #Glioblastoma #GBM #BrainCancer #BrainTumor #CancerResearch #Oncology #ClinicalTrials #BrainCancerAwarenessMonth #GrayMay #GoGrayInMay #BTAM #BrainTumorStrong #PSTV #NeuroOncology #BrainTumorSurgeon #ToralPatel #UTSouthwestern #TargetedTherapy